Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and Patients.
Journal: Clinical pharmacology and therapeutics
Published: March 26, 2025
Predicting live birth for poor ovarian responders: the PROsPeR concept.
Journal: Reproductive biomedicine online
Published: July 18, 2017
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.
Journal: European heart journal
Published: December 25, 2013
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Journal: Journal of the American College of Cardiology
Published: April 04, 2013
Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Journal: Circulation
Published: October 13, 2012
Showing 1-5 of 5
Last Updated: 09/26/2026